GO
| HSI1 | 25,311.21 | -18.52 | 216.69B |
| HSCEI1 | 8,450.10 | -12.54 | 66.58B |
| Back Zoom + Zoom - Block Traded | |
|
PEGBIO CO-B (02565.HK) Enters Joint R&D Collaboration With SN BioScience
2026-09-02 17:05:12 PEGBIO CO-B (02565.HK) announced that it has entered into a material transfer agreement with SN BioScience, a South Korean biotechnology company focused on the development of differentiated therapeutic platforms for obesity and metabolic diseases as well as oncology. Under the agreement, SN BioScience will apply its self-developed sphingosine nucleic acid long-acting drug delivery platform to three self-developed innovative peptide candidates for metabolic diseases of the group, including APGP6. The two parties will conduct joint research on formulations and long-acting delivery of the related candidates to evaluate the in vivo performance, pharmacokinetic characteristics and further development potential of the combinations of the candidates and the platform. They will also explore the possibility of further enhancing product differentiation and development value through the integration of innovative molecules and long-acting delivery technology.(ha/u)~ AASTOCKS Financial News Website: www.aastocks.com This article was automatically translated by AI, the Chinese version should be considered the authoritative version. AASTOCKS.com Limited does not guarantee its accuracy or completeness and accepts no liability for any damages or losses arising from the use of this translation. | |